References
- Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003;48:209-231.
- Greenough A. Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO. Pediatr Resp Rev. 2009;10:26-28.
- Wiśniewska-Ligier A, Woźniakowska-Gęsicka T, Andrzejewski A, Wróblewska W. RSV infections remain dangerous. Article in Polish. Klin Pediatr 2008;16:42-46.
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55.
- Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:556-569.
- Rutkowska M, Helwich E, Borecka R, Gadzinowski J, Polak K, Czyżewska M, Kościesza A, Kornacka MK, Klimek M. Incidence of respiratory infections in children with bronchopulmonary dysplasia receiving prophylaxis with palivizumab. Article in Polish. Ped Pol. 2011;86:317-325.
- Borecka R, Lauterbach R, Helwich E. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland. Dev Period Med. 2016;20:181-190.
- Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL; CARESS investigators. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2015;34:e290-297.
- Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab outcomes Study Group. Pediatr Infect Dis J. 2000;19:1068-1071.
- Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes Registry. J Perinatol. 2008;28:511-517.
- Simon A, Nowak H, Sterz R. Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr. 2011;223:292-298.
- Pignotti MS, Indolfi G, Donzelli G. Factors impacting compliance with palivizumab prophylaxis. Pediatr Infect Dis J. 2004;23:186-187.
- Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118-S126.
- Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512-518.
- Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung-function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988;319:1112-1117.
- Giardino AP, Tran XG, Whitmire DA. Respiratory syncytial virus prevention outreach project. Tex Med 2009;105:e1.
- Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V. Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants. Article in French. Arch Pediatr. 2015;22:146-153.
- Lundeen K, Pfeiffenberger T, Jacobson Vann J, O’Brien T, Sampson C, Wegner S. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program. J Manag Care Pharm. 2013;19:115-124.